
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
2
Neutral
7
Bullish
5
Bearish
13
Neutral
8
Bullish
25
Bearish
11
Neutral
1
Bullish
20
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
9 Cr
Low Risk
—
30.9
—
1.9
3.45
1.90
Sales CAGR
1Y
-73.35%
3Y
-31.48%
5Y
-20.78%
10Y
—
Profit CAGR
1Y
-221.82%
3Y
—
5Y
—
10Y
—
ROE
TTM
-6.62%
3Y
1.46%
5Y
3.71%
10Y
0.35%
ROCE
TTM
-0.04%
3Y
10.93%
5Y
14.12%
10Y
10.32%
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Vivanza Biosciences Ltd (VIVANZA) is currently trading at 2.21 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Vivanza Biosciences Limited is a pharmaceutical company focusing on both novel and generic pharmaceutical products. Established in 1982, it has faced challenges but rebranded to expand its market reach globally. The company has undertaken a significant capacity expansion project, tripling its production capabilities from 18 lac pa to 54 lac pa. Vivanza Biosciences conducted a public issue to raise funds for expansion, showcasing strategic growth ambitions. The acquisition of Vivanza Lifesciences Private Limited marks a strategic step in enhancing its product portfolio and market reach.
Over the past 52 weeks, Vivanza Biosciences Ltd has traded between a low of ₹1.90 and a high of ₹3.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Vivanza Biosciences Ltd has a market capitalization of approximately 8.84. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Vivanza Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
You can buy shares of Vivanza Biosciences Ltd (VIVANZA) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.
Based on its market capitalization of 8.84 Cr, Vivanza Biosciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Vivanza Biosciences Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Vivanza Biosciences Ltd is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Vivanza Biosciences Ltd currently does not pay dividends. Companies that do not pay dividends often reinvest profits to support business growth or strengthen operations.
Key risks associated with Vivanza Biosciences Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.
Performance
UNDER PERFORMER
Valuation
REASONABLE
Growth
STABLE
Profitability
MODERATE MARGIN
Technicals
Bullish
Risk
LOW RISK

Market Cap
₹ 9 Cr
P/E
—